Cargando…

Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction

OBJECTIVE: Atrial fibrillation (AF) and myocardial infarction (MI) are commonly comorbid and associated with adverse outcomes. Little is known about the impact of AF on quality of life and outcomes post-MI. We compared characteristics, quality of life and clinical outcomes in stable patients post-MI...

Descripción completa

Detalles Bibliográficos
Autores principales: Carnicelli, Anthony P, Owen, Ruth, Pocock, Stuart J, Brieger, David B, Yasuda, Satoshi, Nicolau, Jose Carlos, Goodman, Shaun G, Cohen, Mauricio G, Simon, Tabassome, Westermann, Dirk, Hedman, Katarina, Andersson Sundell, Karolina, Granger, Christopher B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679122/
https://www.ncbi.nlm.nih.gov/pubmed/34911791
http://dx.doi.org/10.1136/openhrt-2021-001726
_version_ 1784616450181300224
author Carnicelli, Anthony P
Owen, Ruth
Pocock, Stuart J
Brieger, David B
Yasuda, Satoshi
Nicolau, Jose Carlos
Goodman, Shaun G
Cohen, Mauricio G
Simon, Tabassome
Westermann, Dirk
Hedman, Katarina
Andersson Sundell, Karolina
Granger, Christopher B
author_facet Carnicelli, Anthony P
Owen, Ruth
Pocock, Stuart J
Brieger, David B
Yasuda, Satoshi
Nicolau, Jose Carlos
Goodman, Shaun G
Cohen, Mauricio G
Simon, Tabassome
Westermann, Dirk
Hedman, Katarina
Andersson Sundell, Karolina
Granger, Christopher B
author_sort Carnicelli, Anthony P
collection PubMed
description OBJECTIVE: Atrial fibrillation (AF) and myocardial infarction (MI) are commonly comorbid and associated with adverse outcomes. Little is known about the impact of AF on quality of life and outcomes post-MI. We compared characteristics, quality of life and clinical outcomes in stable patients post-MI with/without AF. METHODS/RESULTS: The prospective, international, observational TIGRIS (long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease) registry included 8406 patients aged ≥50 years with ≥1 atherothrombotic risk factor who were 1–3 years post-MI. Patient characteristics were summarised by history of AF. Quality of life was assessed at baseline using EQ-5D. Clinical outcomes over 2 years of follow-up were compared. History of AF was present in 702/8277 (8.5%) registry patients and incident AF was diagnosed in 244/7575 (3.2%) over 2 years. Those with AF were older and had more comorbidities than those without AF. After multivariable adjustment, patients with AF had lower self-reported quality-of-life scores (EQ-5D UK-weighted index, visual analogue scale, usual activities and pain/discomfort) than those without AF. CHA(2)DS(2)-VASc score ≥2 was present in 686/702 (97.7%) patients with AF, although only 348/702 (49.6%) were on oral anticoagulants at enrolment. Patients with AF had higher rates of all-cause hospitalisation (adjusted rate ratio 1.25 [1.06–1.46], p=0.008) over 2 years than those without AF, but similar rates of mortality. CONCLUSIONS: In stable patients post-MI, those with AF were commonly undertreated with oral anticoagulants, had poorer quality of life and had increased risk of clinical outcomes than those without AF. TRIAL REGISTRATION NUMBER: ClinicalTrials: NCT01866904.
format Online
Article
Text
id pubmed-8679122
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86791222022-01-04 Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction Carnicelli, Anthony P Owen, Ruth Pocock, Stuart J Brieger, David B Yasuda, Satoshi Nicolau, Jose Carlos Goodman, Shaun G Cohen, Mauricio G Simon, Tabassome Westermann, Dirk Hedman, Katarina Andersson Sundell, Karolina Granger, Christopher B Open Heart Coronary Artery Disease OBJECTIVE: Atrial fibrillation (AF) and myocardial infarction (MI) are commonly comorbid and associated with adverse outcomes. Little is known about the impact of AF on quality of life and outcomes post-MI. We compared characteristics, quality of life and clinical outcomes in stable patients post-MI with/without AF. METHODS/RESULTS: The prospective, international, observational TIGRIS (long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease) registry included 8406 patients aged ≥50 years with ≥1 atherothrombotic risk factor who were 1–3 years post-MI. Patient characteristics were summarised by history of AF. Quality of life was assessed at baseline using EQ-5D. Clinical outcomes over 2 years of follow-up were compared. History of AF was present in 702/8277 (8.5%) registry patients and incident AF was diagnosed in 244/7575 (3.2%) over 2 years. Those with AF were older and had more comorbidities than those without AF. After multivariable adjustment, patients with AF had lower self-reported quality-of-life scores (EQ-5D UK-weighted index, visual analogue scale, usual activities and pain/discomfort) than those without AF. CHA(2)DS(2)-VASc score ≥2 was present in 686/702 (97.7%) patients with AF, although only 348/702 (49.6%) were on oral anticoagulants at enrolment. Patients with AF had higher rates of all-cause hospitalisation (adjusted rate ratio 1.25 [1.06–1.46], p=0.008) over 2 years than those without AF, but similar rates of mortality. CONCLUSIONS: In stable patients post-MI, those with AF were commonly undertreated with oral anticoagulants, had poorer quality of life and had increased risk of clinical outcomes than those without AF. TRIAL REGISTRATION NUMBER: ClinicalTrials: NCT01866904. BMJ Publishing Group 2021-12-15 /pmc/articles/PMC8679122/ /pubmed/34911791 http://dx.doi.org/10.1136/openhrt-2021-001726 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Coronary Artery Disease
Carnicelli, Anthony P
Owen, Ruth
Pocock, Stuart J
Brieger, David B
Yasuda, Satoshi
Nicolau, Jose Carlos
Goodman, Shaun G
Cohen, Mauricio G
Simon, Tabassome
Westermann, Dirk
Hedman, Katarina
Andersson Sundell, Karolina
Granger, Christopher B
Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
title Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
title_full Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
title_fullStr Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
title_full_unstemmed Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
title_short Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
title_sort atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
topic Coronary Artery Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679122/
https://www.ncbi.nlm.nih.gov/pubmed/34911791
http://dx.doi.org/10.1136/openhrt-2021-001726
work_keys_str_mv AT carnicellianthonyp atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT owenruth atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT pocockstuartj atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT briegerdavidb atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT yasudasatoshi atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT nicolaujosecarlos atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT goodmanshaung atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT cohenmauriciog atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT simontabassome atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT westermanndirk atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT hedmankatarina atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT anderssonsundellkarolina atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction
AT grangerchristopherb atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction